WO2006061219A3 - Il-7 variants with reduced immunogenicity - Google Patents

Il-7 variants with reduced immunogenicity Download PDF

Info

Publication number
WO2006061219A3
WO2006061219A3 PCT/EP2005/013145 EP2005013145W WO2006061219A3 WO 2006061219 A3 WO2006061219 A3 WO 2006061219A3 EP 2005013145 W EP2005013145 W EP 2005013145W WO 2006061219 A3 WO2006061219 A3 WO 2006061219A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
reduced immunogenicity
molecules
modified
immunogenicity
Prior art date
Application number
PCT/EP2005/013145
Other languages
French (fr)
Other versions
WO2006061219A2 (en
Inventor
Stephen D Gillies
Jeffrey C Way
Original Assignee
Merck Patent Gmbh
Stephen D Gillies
Jeffrey C Way
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Stephen D Gillies, Jeffrey C Way filed Critical Merck Patent Gmbh
Priority to BRPI0519000-2A priority Critical patent/BRPI0519000A2/en
Priority to EP05850240A priority patent/EP1819728B1/en
Priority to CA2591297A priority patent/CA2591297C/en
Priority to JP2007544816A priority patent/JP4937132B2/en
Priority to AT05850240T priority patent/ATE465176T1/en
Priority to DE602005020837T priority patent/DE602005020837D1/en
Priority to CN2005800422055A priority patent/CN101072793B/en
Priority to AU2005313492A priority patent/AU2005313492B2/en
Publication of WO2006061219A2 publication Critical patent/WO2006061219A2/en
Publication of WO2006061219A3 publication Critical patent/WO2006061219A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention relates generally to IL-7 molecules modified to reduce their immunogenicity. These molecules include also fusion proteins comprising said modified IL-7 molecules and immunoglobulin molecules or portions thereof.
PCT/EP2005/013145 2004-12-09 2005-12-08 Il-7 variants with reduced immunogenicity WO2006061219A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0519000-2A BRPI0519000A2 (en) 2004-12-09 2005-12-08 reduced immunogenicity il-7 variants
EP05850240A EP1819728B1 (en) 2004-12-09 2005-12-08 Il-7 variants with reduced immunogenicity
CA2591297A CA2591297C (en) 2004-12-09 2005-12-08 Il-7 variants with reduced immunogenicity
JP2007544816A JP4937132B2 (en) 2004-12-09 2005-12-08 IL-7 variants with reduced immunogenicity
AT05850240T ATE465176T1 (en) 2004-12-09 2005-12-08 IL-7 VARIANTS WITH REDUCED IMMUNOGENITY
DE602005020837T DE602005020837D1 (en) 2004-12-09 2005-12-08 IL-7 VARIANTS WITH REDUCED IMMUNOGENITY
CN2005800422055A CN101072793B (en) 2004-12-09 2005-12-08 Il-7 variants with reduced immunogenicity
AU2005313492A AU2005313492B2 (en) 2004-12-09 2005-12-08 IL-7 variants with reduced immunogenicity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63447004P 2004-12-09 2004-12-09
US60/634,470 2004-12-09

Publications (2)

Publication Number Publication Date
WO2006061219A2 WO2006061219A2 (en) 2006-06-15
WO2006061219A3 true WO2006061219A3 (en) 2007-01-11

Family

ID=36578271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/013145 WO2006061219A2 (en) 2004-12-09 2005-12-08 Il-7 variants with reduced immunogenicity

Country Status (14)

Country Link
US (1) US7589179B2 (en)
EP (1) EP1819728B1 (en)
JP (1) JP4937132B2 (en)
KR (1) KR20070085886A (en)
CN (1) CN101072793B (en)
AT (1) ATE465176T1 (en)
AU (1) AU2005313492B2 (en)
BR (1) BRPI0519000A2 (en)
CA (1) CA2591297C (en)
DE (1) DE602005020837D1 (en)
ES (1) ES2342964T3 (en)
RU (1) RU2437893C2 (en)
WO (1) WO2006061219A2 (en)
ZA (1) ZA200705559B (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
DK1252192T3 (en) 2000-02-11 2006-11-20 Merck Patent Gmbh Enhancement of the serum half-life of antibody-based fusion proteins
EP1324779B1 (en) 2000-09-29 2011-07-20 Schering Corporation Pegylated interleukin-10
MXPA03008031A (en) * 2001-03-07 2003-12-04 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety.
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DK1383785T3 (en) * 2001-05-03 2011-05-23 Merck Patent Gmbh Recombinant tumor-specific antibody and its use
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
BRPI0418286A (en) * 2003-12-30 2007-05-02 Merck Patent Gmbh il-7 fusion proteins
KR20060124656A (en) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 Fc-erythropoietin fusion protein with improved pharmacokinetics
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
KR20070085886A (en) 2004-12-09 2007-08-27 메르크 파텐트 게엠베하 Il-7 variants with reduced immunogenicity
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
ATE555125T1 (en) * 2005-12-30 2012-05-15 Merck Patent Gmbh INTERLEUKIN 12P40 VARIANTS WITH IMPROVED STABILITY
JP2009521912A (en) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-CD19 antibody with reduced immunogenicity
ES2606034T3 (en) 2006-09-28 2017-03-17 Merck Sharp & Dohme Corp. Pegylated IL-10 for use in the treatment of lymphoma
KR100888022B1 (en) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 Fusion Proteion of Imunoglobulin Fc and Human Apolipoproteina Kringle Fragment
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
AU2010238858A1 (en) * 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
TWI486171B (en) * 2009-05-04 2015-06-01 亞培研究公司 Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
US10080799B2 (en) * 2010-02-12 2018-09-25 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
WO2012128806A1 (en) * 2010-12-10 2012-09-27 University Of Central Florida Research Foundation, Inc. Methods and compositions comprising il-7 receptor ligands
EA201490399A1 (en) 2011-08-03 2014-06-30 Ситерис HCV Immunotherapy (Hepatitis C Virus)
CN105209054A (en) 2013-04-18 2015-12-30 阿尔莫生物科技股份有限公司 Methods of using interleukin-10 for treating diseases and disorders
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
KR20160079114A (en) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 Methods of using interleukin-10 for treating diseases and disorders
CN109293782A (en) 2014-01-08 2019-02-01 德益阳光生物技术（北京）有限责任公司 Fused polypeptide and application method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
EP3209320B1 (en) 2014-10-22 2023-03-08 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AU2016228555B2 (en) * 2015-03-11 2021-12-23 Nektar Therapeutics Conjugates of an IL-7 moiety and a polymer
EP3302547A1 (en) 2015-05-28 2018-04-11 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
WO2016200219A1 (en) 2015-06-11 2016-12-15 Genexine, Inc. Modified interleukin-7 protein and uses thereof
KR102386735B1 (en) * 2015-11-06 2022-04-14 주식회사 제넥신 Formulation for modified interleukin-7 fusion protein
CN108697764A (en) 2015-12-04 2018-10-23 格纳西尼有限公司 The pharmaceutical composition for preventing or treating influenza infection of interleukin 7 fusion protein is merged containing immunoglobulin FC
CN108697765A (en) 2015-12-04 2018-10-23 格纳西尼有限公司 The pharmaceutical composition that IL-7 fusion proteins are merged containing immunoglobulin FC for preventing or treating disease caused by human papilloma virus
AU2017238172A1 (en) * 2016-03-21 2018-09-13 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3568417A4 (en) * 2018-01-25 2020-07-15 I-Mab Biopharma US Limited Anti-pd-l1 antibody and il-7 fusions
KR20210093950A (en) 2018-11-16 2021-07-28 네오이뮨텍, 인코퍼레이티드 Methods of Treating Tumors with a Combination of IL-7 Protein and Immune Checkpoint Inhibitors
KR20210108978A (en) 2018-12-21 2021-09-03 오제 이뮈노테라프틱스 Bifunctional Anti-PD-1/IL-7 Molecules
US11512122B2 (en) 2019-05-17 2022-11-29 Xencor, Inc. IL-7-FC-fusion proteins
TW202136287A (en) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 Bifunctional molecules comprising an il-7 variant
CN114945409A (en) 2020-01-13 2022-08-26 新免疫技术有限公司 Methods of treating tumors with combinations of IL-7 proteins and bispecific antibodies
CA3166816A1 (en) 2020-02-03 2021-08-12 William J. Dower Il-7r.alpha..gamma.c binding compounds
EP4100046A4 (en) * 2020-02-03 2024-03-06 Medikine Inc IL-7R alpha BINDING COMPOUNDS
EP4100045A1 (en) 2020-02-05 2022-12-14 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
CR20220512A (en) * 2020-04-15 2022-11-07 Hoffmann La Roche Immunoconjugates
US20210324027A1 (en) * 2020-04-16 2021-10-21 Genexine, Inc. Modified interleukin-7 proteins and uses thereof
KR20230098201A (en) 2020-10-26 2023-07-03 네오이뮨텍, 인코퍼레이티드 Methods of inducing stem cell mobilization
KR20230104176A (en) 2020-11-02 2023-07-07 네오이뮨텍, 인코퍼레이티드 Use of interleukin-7 for treatment of coronavirus
CN116615236A (en) 2020-11-05 2023-08-18 新免疫技术有限公司 Methods of treating tumors using combinations of IL-7 proteins and nucleotide vaccines
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
KR20230129441A (en) 2020-12-17 2023-09-08 오제 이뮈노테라프틱스 Bifunctional anti-PD1/IL-7 molecule
WO2022214653A1 (en) * 2021-04-09 2022-10-13 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4469797A (en) 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US5082658A (en) 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
US5679543A (en) 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5359035A (en) 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
ZA887773B (en) * 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6750329B1 (en) 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ATE123065T1 (en) 1989-07-07 1995-06-15 Takeda Chemical Industries Ltd PROTEINS AND THEIR PRODUCTION.
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
EP0464533B1 (en) * 1990-06-28 1998-07-29 Hoechst Aktiengesellschaft Fusionproteins with parts of immunoglobulins, their production and use
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US20020037558A1 (en) 1991-10-23 2002-03-28 Kin-Ming Lo E.coli produced immunoglobulin constructs
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
ATE311895T1 (en) 1992-05-26 2005-12-15 Immunex Corp NEW CYTOKINE THAT BINDS CD30
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
DE4228839A1 (en) 1992-08-29 1994-03-03 Behringwerke Ag Methods for the detection and determination of mediators
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
AU712585B2 (en) 1995-03-10 1999-11-11 Genentech Inc. Receptor activation by gas6
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
ES2176574T3 (en) 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt USE OF BI AND TRIESPECIFIC ANTIBODIES FOR INDUCTION OF TUMOR IMMUNITY.
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2312188C (en) 1997-12-08 2010-06-29 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
BR9909583A (en) 1998-04-15 2002-01-15 Lexigen Pharm Corp Increased immune response mediated by an antibody-cytokine fusion protein by coadministration with angiogenesis inhibitor
CZ20003817A3 (en) 1998-04-17 2002-08-14 Lexigen Pharmaceuticals Corporation Medicament for inducing cytokine immune response
US6284536B1 (en) 1998-04-20 2001-09-04 The Regents Of The University Of California Modified immunoglobin molecules and methods for use thereof
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
AU761027B2 (en) 1998-08-25 2003-05-29 Merck Patent Gmbh Expression and export of angiostatin and endostatin as immunofusis
US6646113B1 (en) 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US6335176B1 (en) 1998-10-16 2002-01-01 Pharmacopeia, Inc. Incorporation of phosphorylation sites
BR0007414A (en) 1999-01-07 2001-10-16 Lexigen Pharm Corp Expression and export of anti-obesity proteins as fc fusion proteins
KR100773109B1 (en) 1999-05-06 2007-11-02 웨이크 포리스트 유니버시티 Compositions And Methods For Identifying Antigens Which Elicit An Immune Response
CZ20014123A3 (en) 1999-05-19 2002-06-12 Lexigen Pharmaceuticals Corp. Expression and export of alpha interferons as Fc fusion proteins
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6617135B1 (en) 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
DK1252192T3 (en) 2000-02-11 2006-11-20 Merck Patent Gmbh Enhancement of the serum half-life of antibody-based fusion proteins
ATE333900T1 (en) 2000-02-24 2006-08-15 Philogen Spa COMPOSITIONS AND METHODS FOR TREATING ANGIOGENESIS IN PATHOLOGICAL DEFECTS
US20020019342A1 (en) 2000-05-12 2002-02-14 Robert Bayer In vitro modification of glycosylation patterns of recombinant glycopeptides
BR0112111A (en) 2000-06-29 2003-05-06 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein-mediated immune responses by combined treatment with immunocytocin uptake enhancers
MXPA03006294A (en) 2001-01-18 2003-09-16 Merck Patent Gmbh Bifunctional fusion proteins with glucocerebrosidase activity.
EP1366455B1 (en) 2001-02-19 2008-07-02 MERCK PATENT GmbH Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
MXPA03007323A (en) 2001-02-19 2003-12-12 Merck Patent Gmbh Artificial proteins with reduced immunogenicity.
MXPA03008031A (en) 2001-03-07 2003-12-04 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety.
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DE10119338A1 (en) 2001-04-20 2002-10-24 Clariant Gmbh Use of copolymers based on acrylamidoalkylsulfonic acids as thickeners in preparations containing organic solvents
DK1383785T3 (en) 2001-05-03 2011-05-23 Merck Patent Gmbh Recombinant tumor-specific antibody and its use
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
JP4494977B2 (en) 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Humanized antibody (H14.18) of mouse 14.18 antibody that binds to GD2 and its IL-2 fusion protein
US20050069521A1 (en) 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
BRPI0418286A (en) 2003-12-30 2007-05-02 Merck Patent Gmbh il-7 fusion proteins
KR20060124656A (en) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 Fc-erythropoietin fusion protein with improved pharmacokinetics
EP1706428B1 (en) 2004-01-22 2009-09-23 MERCK PATENT GmbH Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
KR20070085886A (en) 2004-12-09 2007-08-27 메르크 파텐트 게엠베하 Il-7 variants with reduced immunogenicity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALPDOGAN ONDER ET AL: "IL-7 and IL-15: therapeutic cytokines for immunodeficiency.", TRENDS IN IMMUNOLOGY. JAN 2005, vol. 26, no. 1, January 2005 (2005-01-01), pages 56 - 64, XP002407226, ISSN: 1471-4906 *
BARCHAM G J ET AL: "Cloning and expression of a cDNA encoding ovine interleukin 7.", GENE. 10 MAR 1995, vol. 154, no. 2, 10 March 1995 (1995-03-10), pages 265 - 269, ISSN: 0378-1119 *
DATABASE EMBL [online] 4 December 2002 (2002-12-04), "Bos taurus IL-7 mRNA, complete cds.", XP002407230, retrieved from EBI accession no. EM_PRO:AF348422 Database accession no. AF348422 *
DATABASE EMBL [online] 8 June 1994 (1994-06-08), "Ovis aries interleukin-7 (IL-7) mRNA, complete cds.", XP002407231, retrieved from EBI accession no. EM_PRO:U10089 Database accession no. U10089 *
STOREK JAN ET AL: "Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys.", BLOOD. 15 MAY 2003, vol. 101, no. 10, 15 May 2003 (2003-05-15), pages 4209 - 4218, XP002407227, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
ES2342964T3 (en) 2010-07-20
US20060141581A1 (en) 2006-06-29
BRPI0519000A2 (en) 2008-12-23
CA2591297A1 (en) 2006-06-15
EP1819728A2 (en) 2007-08-22
JP2008522600A (en) 2008-07-03
US7589179B2 (en) 2009-09-15
EP1819728B1 (en) 2010-04-21
RU2437893C2 (en) 2011-12-27
ZA200705559B (en) 2008-10-29
KR20070085886A (en) 2007-08-27
WO2006061219A2 (en) 2006-06-15
AU2005313492A1 (en) 2006-06-15
CN101072793A (en) 2007-11-14
CA2591297C (en) 2015-01-13
AU2005313492B2 (en) 2011-12-15
JP4937132B2 (en) 2012-05-23
ATE465176T1 (en) 2010-05-15
CN101072793B (en) 2012-06-20
RU2007125381A (en) 2009-01-20
DE602005020837D1 (en) 2010-06-02

Similar Documents

Publication Publication Date Title
WO2006061219A3 (en) Il-7 variants with reduced immunogenicity
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
WO2006105062A3 (en) Altered antibody fc regions and uses thereof
WO2005097825A3 (en) Bmp-7 variants with improved properties
WO2006133088A3 (en) Improved human interferon molecules and their uses
WO2006050959A3 (en) Molecules which promote hematopoiesis
PH12016500081A1 (en) Immunoglobulin variants and uses thereof
WO2007060117A3 (en) Chimeric keratin-binding effector proteins
WO2006082406A3 (en) Human antibodies and proteins
WO2006127757A3 (en) Interferon-igg fusion
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2005047314A3 (en) Fgf-beta binding and supported peptides
HK1102306A1 (en) Modified bouganin proteins, cytotoxins and methods and uses thereof
TWI370136B (en) Il-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses
MXPA03007319A (en) Modified anti-egfr antibodies with reduced immunogenicity.
WO2004099249A3 (en) Optimized fc variants and methods for their generation
WO2006053301A3 (en) Fc variants with altered binding to fcrn
WO2007133290A8 (en) Anti-ox40l antibodies and methods using same
WO2005074650A3 (en) Modified human four helical bundle polypeptides and their uses
WO2007082923A3 (en) Use of protein microbeads in cosmetics
WO2009142460A3 (en) Antibody-peptide fused synergibody
WO2004085478A3 (en) Improved fc fusion proteins
WO2007029200A9 (en) Ssb - polymerase fusion proteins
IL190773A0 (en) An antibody or antibody fragment-targeted cationic immunolysome complex and methods of preparing the same
WO2004031352A3 (en) Interferon variants with improved properties

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005850240

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12007500817

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/006631

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2591297

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007544816

Country of ref document: JP

Ref document number: 200580042205.5

Country of ref document: CN

Ref document number: 1020077012885

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2516/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005313492

Country of ref document: AU

Ref document number: 2007125381

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2005313492

Country of ref document: AU

Date of ref document: 20051208

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005313492

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005850240

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0519000

Country of ref document: BR